Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects

NCT02502812 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease

Interventions

DRUG: Clop F1
DRUG: Clop F2
DRUG: Innovator

Sponsor

GlaxoSmithKline